Advertisement


Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials

COVID-19 and Cancer Care

Advertisement

Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma­­—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.



Related Videos

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 1

How has the COVID-19 pandemic changed your approach to the selection of tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia?

Recorded April 24, 2020.

Multiple Myeloma
COVID-19

Saad Z. Usmani, MD: In My Experience Question 4

For patients with multiple myeloma who are currently on clinical trials, what are the most pressing issues as we fight COVID-19?

Recorded April 24, 2020.

Lymphoma
COVID-19

Mehdi Hamadani, MD: In My Experience Question 5

For community oncologists treating patients with non-Hodgkin lymphoma during the COVID-19 pandemic, what resources and clinical pearls would you suggest?

Recorded April 21, 2020.

COVID-19
Global Cancer Care

Giorgio V. Scagliotti, MD, PhD, on the Ongoing Battle Against COVID-19: Update From Italy

Giorgio V. Scagliotti, MD, PhD, of the University of Turin, talks about the ways in which coronavirus reshaped Italian hospitals, mistakes made, and lessons learned. Filmed April 15, 2020.

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 5

For community oncologists treating patients with chronic myeloid leukemia or chronic lymphocytic leukemia during the COVID-19 pandemic, what resources and clinical pearls would you suggest?

Recorded April 24, 2020.

Advertisement

Advertisement




Advertisement